Drug-Induced Sleep Endoscopy in Obstructive Sleep Apnea (AMW) Session
2021 AAO-HNSF Annual Meeting & OTO Experience
A goal of obstructive sleep apnea surgical evaluation is the identification of the pattern of upper airway obstruction. By addressing airway obstruction in a targeted fashion, it may be possible to tailor surgical treatment to a patient's specific pattern of obstruction--improving surgical results and/or minimizing the scope of surgical intervention. Compared to other commonly used evaluation techniques, drug-induced sleep endoscopy (DISE) has the unique advantage of providing a dynamic assessment under sleep-like conditions to evaluate the structures contributing to airway obstruction. The session will include a detailed discussion of the VOTE Classification that the panelists developed. DISE evaluation is aided by several specific passive maneuvers, including various mandible, head, and body positions. Technical pearls based on the panelists' experience with more than 10,000 DISE procedures will be presented, along with example videos of typical and unique pathologic findings. The second half of the session will incorporate an interactive discussion based on sample DISE videos, allowing attendees to develop a comfort level with characterizing DISE findings using the VOTE Classification. The strengths and limitations of DISE will be discussed, based on a literature review and presentation of recent research findings. The session will incorporate a discussion of the use of DISE in procedure selection, including hypoglossal nerve stimulation, as well as DISE during CPAP administration.
Description
Learning Objective: 1. Understand how DISE can improve the selection of surgical procedures and oral appliances in the treatment of OSA. 2. Use the VOTE Classification to characterize DISE findings and understand their implications. 3. Initiate DISE program or consider DISE technique modifications in your practice. Faculty: Winfried Hohenhorst, MD(Nothing to Disclose), Nico de Vries, MD, PhD(Nothing to Disclose), Eric Kezirian, MD, MPH(Intellectual Property Rights: Berendo Scientific, Magnap; Research Funding: Inspire Medical Systems; Stock or Stock Options: Berendo Scientific, Cognition Life Science, CryOSA, Pillar Palatal).